Encouraging Phase III Data Reported For Vanda’s Schizophrenia Candidate
This article was originally published in The Pink Sheet Daily
Executive Summary
Iloperidone could have a potential tolerability advantage over Pfizer’s Geodon.
You may also be interested in...
“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future
FDA requests additional Phase III comparative study and safety data for iloperidone.
“Not Approvable” Letter Leaves Vanda’s Schizophrenia Drug With Cloudy Future
FDA requests additional Phase III comparative study and safety data for iloperidone.
Titan’s Spheramine Fails In Parkinson’s
Partner Bayer Schering drops compound after Phase IIb fizzle.